Analgesia aNd caNcer recUrrence Lung cAncer Resection

The choice of analgesia after cancer surgery may play a role in the onset of recurrence, particularly opioids seem to play a role in the immune system by promoting cancer cell proliferation and migration. Based on this consideration, our aim was to assess the impact of perioperative analgesia's choice on cancer recurrence after curative surgery for Stage I Non-Small Cell Lung Cancer. The investigators retrospectively reviewed the records of patients who underwent lung resection for Stage I NSCLC between January 2005 and December 2012. Patients received analgesia either by peridural (PERI group) or, in case of patient refusal or failure in catheter positioning, intravenous analgesia with opioids (EV group). Follow-up was concluded in August 2019. The five-year cumulative incidence of recurrence and the overall survival were evaluated and adjusted with a propensity score matching methodology.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Recurrence Tumor Agnosia Analgesia Disease Attributes Nervous System Diseases Neurobehavioral Manifestations Neurologic Manifestations Opioid Use, Unspecified Pathologic Processes Pathological Conditions, Signs and Symptoms Perceptual Disorders Recurrence Signs and Symptoms Thoracic Surgery

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

AOU Città della Salute e della Scienza di Torino

Torino, 10100, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 18 yrs
Patients who underwent lung resection for Stage I NSCLC between January 2005 and December 2012

Exclusion criteria

Age<18aa
Pregnancy
Day hospital patients

Treatment and study plan

Peridural analgesia

Procedure

We attempted to evaluate the effectiveness of peridural analgesia through cancer survival and recurrence outcomes.

Primary outcomes

cumulative incidence of recurrence and the overall survival

Time frame: 5 years

Sponsors and collaborators

Lead sponsor

University of Turin, Italy

Other

Registry information

Official study title

Impact of Analgesia on Cancer Recurrence and Mortality Within Five Years After Stage I Non-Small Cell Lung Cancer Resection

Important dates

Study start: 2018
Primary completion: 2020
Study completion: 2020
First posted: Dec 7, 2020
Registry last updated: Dec 21, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed